# Daniel Eriksson

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daniel-eriksson/

## Facts

| Field | Value |
| --- | --- |
| Citations | 822 |
| Field | Atrial Fibrillation Management and Outcomes |
| h-index | 14 |
| i10-index | 18 |
| Last Known Institution | Uppsala University |
| OpenAlex ID | https://openalex.org/A5009397280 |
| ORCID iD | 0000-0001-7699-242X |
| Works | 52 |

## Researcher papers

- [Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis](https://scholariq.org/papers/rivaroxaban-versus-warfarin-in-patients-with-nonvalvular-atrial-fibrillation-and/)
- [Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis](https://scholariq.org/papers/transcription-factor-fra-1-targets-arginase-1-to-enhance-macrophage-mediated/)
- [Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia](https://scholariq.org/papers/cross-sectional-survey-in-ckd-patients-across-europe-describing-the-association/)
- [Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes](https://scholariq.org/papers/rivaroxaban-vs-warfarin-and-renal-outcomes-in-non-valvular-atrial-fibrillation/)
- [Rivaroxaban’s Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis](https://scholariq.org/papers/rivaroxaban-s-impact-on-renal-decline-in-patients-with-nonvalvular-atrial/)
- [Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non‐valvular atrial fibrillation and type 2 diabetes](https://scholariq.org/papers/effectiveness-and-safety-of-rivaroxaban-and-warfarin-for-prevention-of-major/)
- [Health-related quality of life across all stages of autosomal dominant polycystic kidney disease](https://scholariq.org/papers/health-related-quality-of-life-across-all-stages-of-autosomal-dominant/)
- [Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease](https://scholariq.org/papers/effectiveness-and-safety-of-rivaroxaban-vs-warfarin-in-patients-with-non/)
- [Effectiveness and safety of rivaroxaban vs warfarin in people with non‐valvular atrial fibrillation and diabetes: an administrative claims database analysis](https://scholariq.org/papers/effectiveness-and-safety-of-rivaroxaban-vs-warfarin-in-people-with-non-valvular/)
- [Real-world costs of autosomal dominant polycystic kidney disease in the Nordics](https://scholariq.org/papers/real-world-costs-of-autosomal-dominant-polycystic-kidney-disease-in-the-nordics/)

## Researcher topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Hemophilia Treatment and Research](https://scholariq.org/topics/hemophilia-treatment-and-research/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)

## Researcher university

- [Uppsala University](https://scholariq.org/institutions/uppsala-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.